🚚 Free Tracked 24 on all pens · other orders free over £50, otherwise £5.99 🖊️ Peptide Pens → 🖊️ Retatrutide Pens: 20mg £124.99 · 40mg £159.99 → 🎬 View Peptide Videos → 🔬 New: Senolytics & Longevity Research. Explore the science → 👤 Members save 10% on eligible products. Join free → 🚚 Free Tracked 24 on all pens · other orders free over £50, otherwise £5.99 🖊️ Peptide Pens → 🖊️ Retatrutide Pens: 20mg £124.99 · 40mg £159.99 → 🎬 View Peptide Videos → 🔬 New: Senolytics & Longevity Research. Explore the science → 👤 Members save 10% on eligible products. Join free → 🚚 Free Tracked 24 on all pens · other orders free over £50, otherwise £5.99 🖊️ Peptide Pens → 🖊️ Retatrutide Pens: 20mg £124.99 · 40mg £159.99 → 🎬 View Peptide Videos → 🔬 New: Senolytics & Longevity Research. Explore the science → 👤 Members save 10% on eligible products. Join free →

BPC-157: What the Published Studies Actually Show

Headline card reading What BPC-157 Studies Show, over a small stack of navy and cream journals beside a research vial.

BPC-157: What the Published Studies Actually Show

By the Corex Vitality™ Research Team · Last checked 7 November 2026 · Sources listed under Published Research

Quick summary

  • BPC-157 is a synthetic 15-amino-acid peptide. Almost all published studies on it are in rats and mice.
  • Most of those papers come from one research group in Zagreb, Croatia.
  • Independent reviews call the animal evidence varied and hard to compare, and the human evidence very low certainty.
  • BPC-157 is not an approved medicine. This guide maps the research. It does not discuss personal use.

BPC-157 is one of the most searched research peptides in the UK, and claims about it are everywhere online. This guide looks at what published BPC-157 studies actually contain: how many studies there are, what kind, who did them, and what independent reviewers concluded. It is a map of the evidence, not a summary of benefits. If you are new to peptides, start with What Are Peptides?

1. What BPC-157 is

  • BPC stands for “Body Protection Compound”. BPC-157 is a pentadecapeptide, a chain of 15 amino acids.
  • A 2025 literature and patent review describes it as based on part of a protein found in human gastric juice. The material sold for research is made synthetically.
  • The same review notes that BPC-157 has not been approved by the US FDA or other regulators, because comprehensive studies in people are lacking.

2. The size and shape of the literature

We searched PubMed on 7 November 2026. The numbers below are search counts, so they overlap and include some letters and commentaries, but they show the overall shape:

  • 235 records mention BPC 157 or BPC-157.
  • 176 of them mention rats or mice.
  • 176 list P. Sikirić of the University of Zagreb pharmacology group as an author.
  • 52 are indexed as reviews.
  • 0 are indexed by PubMed as controlled or randomised trials in people.

In short, this is a large animal literature that comes mostly from one group, with many reviews and almost no controlled human data.

The BPC-157 evidence map PubMed search counts, 7 November 2026 (counts overlap) All records235 Mention rats or mice176 Same Zagreb author176 Reviews52 Indexed human trials0 Animal studies (reviews say) Many models, organs and timings Often short, single administration Risk of bias often unclear Needs independent, blinded repeats Human evidence (2026 review) 3 small studies, 30 people in total No control groups Certainty of evidence: very low Not an approved medicine

3. What the animal studies looked at

A 2026 critical review of rodent ischaemia-reperfusion studies (where blood flow to a tissue is stopped and then restored) is a good example of how independent reviewers read this work. Across the studies it found reported changes in:

  • oxidative-stress markers
  • nitric-oxide-related responses in blood vessels
  • inflammatory and apoptosis (cell-death) markers
  • VEGF/VEGFR2-Akt-eNOS signalling, a pathway involved in blood-vessel growth

The same review also listed clear limits. The studies used many different organs, models, amounts, routes and timings, so they could not be combined in a meta-analysis. Many used short observation periods and a single administration, and the risk of bias was often not fully reported. The author called BPC-157 “hypothesis-generating” and said independent, blinded replication would be needed.

A 2025 systematic review from an orthopaedic perspective found a similar picture: of 36 studies that met its criteria, 35 were preclinical (tendon, ligament and bone injury models in animals) and only 1 was clinical.

4. What the human evidence looks like

A 2026 systematic review searched for every study of BPC-157 in people up to 1 June 2026. It found:

  • three small studies with 30 people in total;
  • none had a control group, and all were judged to be of poor methodological quality;
  • the overall certainty of evidence was rated very low.

The authors concluded that BPC-157 should not be used in people outside ethically approved, regulated, high-quality studies. The 2025 orthopaedic review also found no clinical safety data.

5. Quality and supply concerns

The 2025 orthopaedic review pointed out possible risks from unregulated manufacturing and contamination, and the patent review noted that BPC-157 is widely offered for sale online. For laboratory work, that makes batch documentation essential: a named laboratory, a report number you can check, and an HPLC purity result. Our guides on how to verify a peptide COA and laboratory testing explain what to look for.

6. How to read a BPC-157 paper

  • Species and model: was it a cell study, a rat model or a person? Results do not transfer automatically between them.
  • Who did it: has a different, independent group repeated the finding?
  • Design: was there a control group, blinding and a stated sample size?
  • Measures: were the outcomes markers in tissue, or functional results? How long was the follow-up?
  • Material: was the peptide’s source and purity reported?

Key takeaways

  • BPC-157 is a synthetic 15-amino-acid peptide with a large animal literature, mostly from one research group.
  • Independent reviews describe the animal studies as varied, often short, and in need of blinded replication.
  • Human evidence is limited to three small uncontrolled studies (30 people) rated very low certainty; it is not an approved medicine.
  • Batch documentation and COA checks matter because of supply-quality concerns.
  • For in-vitro research, see BPC-157 research vials, BPC-157 UK prices and published research, the TB-500 + BPC-157 blend, the batch verification page and the Learning Hub.

Published Research

The peer-reviewed papers below were used for the science in this article. Each entry was checked against PubMed on 7 November 2026. Summaries describe chemistry, laboratory and cell-based findings only. Corex Vitality™ is not affiliated with the cited authors, journals or institutions.

  1. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Józwiak M, Bauer M, Kamysz W, et al. Pharmaceuticals (Basel). 2025;18(2):185. PMID: 40005999 · DOI: 10.3390/ph18020185
    Literature and patent review describing BPC 157 as a 15-amino-acid peptide based on a sequence from a human gastric-juice protein. Summarises preclinical findings and notes that it has not been approved by the FDA or other regulators because comprehensive human studies are lacking.
  2. BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence. Demirtaş H. Int J Mol Sci. 2026;27(18):8344. PMID: 42794771 · DOI: 10.3390/ijms27188344
    Critical review of rodent ischaemia-reperfusion studies. Reports changes in oxidative-stress, nitric-oxide, inflammatory and apoptotic markers and VEGF/VEGFR2-Akt-eNOS signalling, but describes the evidence as heterogeneous, often short and single-administration, with unclear risk of bias. Meta-analysis was not possible.
  3. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. Vasireddi N, Hahamyan H, Salata MJ, et al. HSS J. 2025;21(4):485-495. PMID: 40756949 · DOI: 10.1177/15563316251355551
    Systematic review from an orthopaedic perspective. Of 36 included studies, 35 were preclinical and 1 was clinical. It found no clinical safety data and noted possible risks from unregulated manufacturing and contamination.
  4. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Poolton JT, Minett J, Kazmi A. Acta Orthop Belg. 2026;92(3). PMID: 42885452 · DOI: 10.52628/92.3.15837
    Systematic review of human evidence up to 1 June 2026. Only three small, uncontrolled studies (30 people in total) met the criteria; all were judged poor quality and the overall certainty of evidence was rated very low.

All Corex Vitality™ products are supplied strictly for in-vitro laboratory research use only. Not for human or veterinary use. No information here describes use in humans or animals.

Cover of the free guide: How to read a COA

Free guide

How to read a COA

Get it by email, plus our research updates. No spam, unsubscribe any time.

We will email you to confirm first, then send the guide. We use your name and email only to send you these emails. Privacy policy. For laboratory research use only.

Listed on PepmarketVerified on PeptideReview